AN2 Therapeutics ANTX 深 滬
已收盤 12-12 16:00:00 美东时间
1.20
+0.010
+0.84%
華盛通- 最 高1.23
- 今 開1.20
- 成交量 7.50万股
- 最 低 1.16
- 昨 收 1.19
- 總市值 3288.24万
- 52周最高 1.55
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.01
- 委 比 -86.30%
- 總股本 2740.20万
- 歷史最高 23.58
- 量 比 0.92
- 振 幅 5.88%
- 歷史最低 0.87
- 每 手 1
- 風險率 0.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AN2 Therapeutics reports Q3 results
AN2 Therapeutics press release (ANTX): Q3 net loss was $9.4 million. The Company had cash, cash equivalents and investments of $65.1 million at September 30, 2025. More on AN2 Therapeutics Seeking Alp...
11-13 23:20
AN2 Therapeutics Q3 EPS $(0.31) Misses $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.30) by 4.73 percent. This is a 27.91 percent increase over losses of $(0.43) per share from
11-13 05:30
AN2 Therapeutics Announces Collaboration Agreement With GSK To Develop New Therapies For TB
AN2 awarded third year of funding from Gates FoundationAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a
11-10 20:11
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies Global Corp. has received regulatory clearance from the Danish Medicines Agency to commence the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial, PARADIGM, for patients with severe calcific aortic stenosis. The trial, expected to begin patient recruitment in 4Q 2025, aims to assess the safety and effectiveness of DurAVR® compared to commercial TAVR devices. Anteris plans to expand the trial across the U.S., Europe...
10-15 13:18
Anterix Announces Executive Leadership Changes to Power Next Phase of Growth
<p>Anterix announced changes in its executive leadership team to enhance its ability to deliver advanced connectivity solutions for critical industries. Heather Martin has been appointed as Chief Marketing Officer and Chief of Staff, bringing over 20 years of global marketing experience. Elena Marquez succeeds Tim Gray as Chief Financial Officer, with a strong background in financial leadership. These appointments aim to strengthen Anterix’s mark...
09-18 11:30
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders from September 4 to September 11, 2025, to allow more time for shareholder voting. The meeting will now be held virtually. Voting details and deadlines have been updated to accommodate the new date. The Company's Board recommends stockholders vote FOR the proposals outlined in the Proxy Statement filed with the SEC on August 18, 2025. The Proxy Statement and relat...
09-04 05:42
AN2 Therapeutics Q2 EPS $(0.21) Beats $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30.69 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
08-13 04:20
Anterix Sets First Quarter Fiscal 2026 Earnings Conference Call for Wednesday, August 13, at 9:00 a.m. ET
<p>Anterix (NASDAQ: ATEX) announced it will host a conference call on August 13, 2025, at 9:00 a.m. ET to discuss its first quarter fiscal 2026 results. A press release will be issued on August 12, 2025. Interested participants must pre-register to join the live Q&A session. The call will be webcast live and available on Anterix’s Investor Relations website. A replay will be posted afterward. Anterix specializes in 900 MHz broadband solutions for...
07-22 15:30
AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime
Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraboroleObservational Study funded by the National Institutes of Health
06-30 19:11
AN2 Therapeutics Unveils Updated Investor Presentation
AN2 Therapeutics, Inc. ( ($ANTX) ) just unveiled an announcement. On June 11, 2...
06-11 19:59
